|
|
|
11-50 employees
View all
|
|
biotechnology
|
|
71 Kingsway,London,England,GB
|
|
The Dementia Discovery Fund (DDF) is a £250million specialist venture capital fund that invests in projects and creates biotech companies to deliver high impact therapeutics for dementia - including Alzheimer’s Disease (AD), Parkinson’s Disease Dementia (PDD), Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s Disease (HD). By making meaningful and sustained investments which are actively managed, the DDF enables the development of therapeutics addressing one of the world’s largest unmet medical needs and the generation of significant returns for its investors. Established in 2015, it has raised funds from an influential group including leading pharmaceutical companies (Biogen, Eli Lilly and Co., GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), along with AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK Government’s Department of Health and Social Care, and the charity Alzheimer’s Research UK. The Fund is managed by SV Health Investors. Learn more at www.TheDDFund.com
|
Dementia Discovery Fund Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Dementia Discovery Fund email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Dementia Discovery Fund customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.